Corbus Pharmaceuticals Holdings, Inc.CRBPNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Accelerating
Trending higher, above historical average, modest growth trend.
Left:
||||
Year-over-year research & development expense growth
Latest
37.35%
↑ 191% above average
Average (39q)
12.84%
Historical baseline
Range
High:114.46%
Low:-68.26%
CAGR
+3.1%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 37.35% |
| Q2 2025 | -2.91% |
| Q1 2025 | 78.01% |
| Q4 2024 | -18.70% |
| Q3 2024 | 57.44% |
| Q2 2024 | 19.14% |
| Q1 2024 | -17.45% |
| Q4 2023 | 6.55% |
| Q3 2023 | 54.18% |
| Q2 2023 | -68.26% |
| Q1 2023 | 114.46% |
| Q4 2022 | 51.96% |
| Q3 2022 | 64.35% |
| Q2 2022 | -23.94% |
| Q1 2022 | -42.98% |
| Q4 2021 | -33.72% |
| Q3 2021 | -22.81% |
| Q2 2021 | 5.08% |
| Q1 2021 | -33.45% |
| Q4 2020 | -41.47% |
| Q3 2020 | -10.31% |
| Q2 2020 | 28.14% |
| Q1 2020 | 1.96% |
| Q4 2019 | 6.03% |
| Q3 2019 | -0.13% |
| Q2 2019 | 1.83% |
| Q1 2019 | 38.04% |
| Q4 2018 | 23.21% |
| Q3 2018 | 24.83% |
| Q2 2018 | 5.06% |
| Q1 2018 | 17.84% |
| Q4 2017 | 47.38% |
| Q3 2017 | -2.45% |
| Q2 2017 | -9.46% |
| Q1 2017 | 18.33% |
| Q4 2016 | 24.67% |
| Q3 2016 | 20.99% |
| Q2 2016 | 64.08% |
| Q1 2016 | 19.24% |
| Q4 2015 | 11.52% |